{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Campath-1H+and+Tacrolimus&page=3", "query": { "intervention": "Campath-1H and Tacrolimus", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 58, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Campath-1H+and+Tacrolimus&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Campath-1H+and+Tacrolimus&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T16:36:02.137Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02435901", "title": "HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Beta Thalassemia-Major" ], "interventions": [ { "name": "alemtuzumab (Campath IH)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Hematopoietic Stem Cell Transplantation", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 29, "start_date": "2008-12", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2021-08-24", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02435901" }, { "nct_id": "NCT00448357", "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "rabbit anti-thymocyte globulin (ATG)", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2005-10", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448357" }, { "nct_id": "NCT00745420", "title": "Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Hematopoietic Stem Cell Transplantation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "3 Years to 19 Years" }, "enrollment_count": 30, "start_date": "2008-08", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2022-12-09", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00745420" }, { "nct_id": "NCT04154735", "title": "Autologous Transplant Targeted Against Crohn's", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Rifaximin", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 0, "start_date": "2019-11", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2019-11-08", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04154735" }, { "nct_id": "NCT06872333", "title": "Allo HSCT for High Risk Hemoglobinopathies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Failure", "Sickle Cell Disease", "Hemoglobinopathies" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Plerixafor (mozobil)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 62, "start_date": "2024-11-19", "completion_date": "2032-06-01", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06872333" }, { "nct_id": "NCT00525876", "title": "Non-Myeloablative Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 49, "start_date": "2005-01", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2011-12-07", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00525876" }, { "nct_id": "NCT00520130", "title": "Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Hodgkin's Lymphoma", "Non-Hodgkin's Disease", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Allogenic stem cell transplant (ASCT)", "type": "DRUG" }, { "name": "Conditioning Chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 92, "start_date": "2007-10-30", "completion_date": "2018-12-31", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520130" }, { "nct_id": "NCT00166556", "title": "A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplantation, Liver" ], "interventions": [ { "name": "Campath-1H and Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2005-01", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2011-05-23", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00166556" }, { "nct_id": "NCT02766465", "title": "Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "r-ATG", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplant", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Standard of Care", "type": "PROCEDURE" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 138, "start_date": "2017-03-16", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 35, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766465" }, { "nct_id": "NCT02867800", "title": "Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease", "Graft Versus Host Disease" ], "interventions": [ { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Meperidine", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Marrow infusion", "type": "PROCEDURE" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Monica Bhatia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "3 Years to 20 Years" }, "enrollment_count": 24, "start_date": "2016-07", "completion_date": "2023-12-30", "has_results": false, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-10-07T16:36:02.137Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02867800" } ] }